• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 09/23/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

TumorGenesis

  • 11:31 AM

    In an Interview with CEOCFO Magazine, CEO Dr. Carl Schwartz Explains how the Company’s Database of Tumors, Artificial Intelligence Technology, and Groundbreaking Method for Growing Human Cancer Cells Makes it a Leader in Personalized Medicine EAGAN, MN / ACCESSWIRE / July 17, 2018 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (NASDAQ: AIPT). As Dr. Schwartz told CEOCFO’s Bud Wayne, Precision Therapeutics has become

    Read more
  • 9:50 AM

    MINNEAPOLIS, May 08, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the fiscal first quarter of 2018 on May 15, 2018 after U.S. markets close. Management will also hold a conference call to provide a general business update and discuss upcoming milestones. The conference call is scheduled to begin at 4:30 p.m. Eastern Time. A

    Read more
  • 4:46 PM

    Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D cell culturing from 48 Hour Discovery, SyntArray and CellBridge MINNEAPOLIS, April 09, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has engaged Richard Gabriel as a consultant to lead the external business development strategy for TumorGenesis, Inc., its

    Read more
  • 9:09 AM

    MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with CellBridge Incorporated (“CellBridge”) which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray, LLC and 48Hour Discovery and is the latest milestone in the Company’s strategy to bring together ground-breaking technologies to develop the next generation of patient derived (“PDx”) tumor models for

    Read more
  • 9:42 AM

    MINNEAPOLIS, March 13, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with SyntArray LLC. This license agreement will advance the Company’s strategic plan to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development by granting it access to SyntArray’s targeted peptide cell capture technology. TumorGenesis is developing a new approach to growing tumor

    Read more
  • 2:40 PM

    SAN DIEGO, CA and LAS VEGAS, NV, July 9, 2015 /PRNewswire/ – Isaac Capital Group LLC (ICG), an international private investment firm based in San Diego, California, today announced that, in connection with Isaac Capital Fund I, LLC, it committed $7Mof bridge financing for LiveDeal Inc. to pursue acquisitions.  Isaac Capital Fund I, LLC is a company controlled by LiveDeal Inc. CEO,Jon Isaac.  The committed capital was earmarked for the first acquisition in LiveDeal and Live Venture Inc.’s recently announced strategy

    Read more
Public Wire Banner